The Hidden Risk in Orthopedic Surface Technology: Manufacturing Reality

Orthopedic innovation continues to push surface technology forward. New coatings, nanotextures, additive manufacturing integrations, and bioactive surfaces all promise improved healing, stronger integration, and better long-term outcomes. From a development standpoint, many of these technologies are incredibly compelling.

Yet there is a reality the industry often overlooks: a surface technology that performs well in the lab does not automatically perform well in manufacturing. The gap between laboratory success and commercial execution is where many technologies can struggle. 

Advanced technologies require specialized expertise to develop, optimize, and translate into production. From an operations perspective, the real question is not whether a surface works under controlled conditions; it is whether it can be produced consistently, repeatedly, and economically across thousands of implants, multiple product lines, evolving supply chains, and years of production scaling.

Anyone with manufacturing experience understands that scaling production inevitably introduces new challenges. As volume increases, processes are tested, and troubleshooting becomes part of the journey. Success often comes down to having the right team in place to identify and solve those issues quickly. 

The True Test of Scalability

In development environments, teams often work with one-off or small batch prototypes using controlled variables and highly specialized oversight. At the other extreme, teams may operate with significant freedom and minimal oversight. While both environments may produce exceptional results for a given surface technology, neither scenario was ever intended for the production environment. 

Scaling manufacturing introduces a vastly different set of variables. Part geometries change, and surface finishes and porosities vary. Upstream manufacturing methods can introduce part-to-part inconsistency, and cleaning effectiveness might differ among suppliers. Operators rotate, equipment utilization rises, and production volumes increase over time. There is also no substitute for sheer volume when it comes to uncovering inherent weaknesses in a process. A process that appeared robust during development can begin showing variation once exposed to this level of manufacturing complexity.

From my seat, one of the most overlooked risks in surface technology is assuming the transition from development to production is simply a matter of scaling capacity. Scaling is where a surface technology’s growth potential really gets tested for the first time. Creating the intended surface once is rarely the challenge. The real challenge is producing it consistently on every part in every batch. 

Manufacturing Risk Begins Upstream

One of the biggest operational lessons I have learned is that the success of a surface technology is often determined long before the surface manufacturing process begins. It is important to stay relevant with manufacturing trends to ensure new surface technologies can accommodate where the industry is heading. Additive manufacturing is a notable example. Highly porous and lattice structures can create tremendous implant effectiveness opportunities, but they also introduce new operational challenges when it comes to surface technology applications. Residual printing particulate, trapped blasting media, inconsistencies in post-processing, and varying cleaning effectiveness can all impact downstream surface performance.

In some cases, residual contamination may shield portions of the surface entirely, preventing the intended nano- or micro-structures from forming consistently. From a development standpoint, this may appear to be a secondary manufacturing issue. From an operational standpoint, it becomes a primary process-control issue. The surface technology may not have failed “scientifically”; it may have failed because the broader manufacturing process and supply chain was not designed around the needs of the surface. 

From product launches to M&A and manufacturing trends, the ODT Now delivers the orthopedic device news you need weekly. Subscribe here!

Why Supply Chains Matter More Than Many Realize

Another misconception is that surface technologies can simply be “added on” at the end of an existing manufacturing process flow with minimal disruption. While this may be true in some situations, surface technologies often require a far more integrated operational approach.

From personal experience, cleaning methods, handling procedures, packaging materials, sterilization strategies, environmental controls, and storage conditions can all influence final surface integrity and performance. High-energy or biologically active surfaces can be sensitive to contamination, hydrocarbon accumulation, or excessive handling after processing. As a result, handling, packaging, and sterilization methods must be considered alongside the surface technology itself. This is true both during technology development and when integrating into a new or existing supply chain. 

The most successful technology integrations are the ones where manufacturing, quality, packaging, and R&D teams are involved early in development rather than after the technology has already been finalized. Too often, organizations attempt to retrofit operational solutions around a finished technology instead of designing the manufacturing ecosystem alongside it. That approach creates friction, delays, added costs, and unnecessary risk.

Broad Applicability Still Requires Discipline

Certain aqueous or electrochemical surface processes offer significant advantages because they can reach complex geometries and porous structures more effectively than traditional line-of-sight applications. That flexibility can create broad applicability across multiple implant types and manufacturing methods. 

However, “universally applicable” does not mean “universally simple.” Every implant design still introduces unique operational variables. Conductive surface area, fixturing methods, geometry orientation, porosity depth, and surface finish characteristics can all influence process behavior and scalability. The industry sometimes underestimates how much engineering and operational discipline is required behind the scenes to make advanced surface technologies appear seamless to the customer. The more sophisticated the biological intent becomes, the more disciplined the manufacturing execution must become alongside it.

Collaboration Drives Scalability

One of the biggest operational mistakes organizations make is treating manufacturing transfer as a handoff. Development creates the process, and operations simply runs it. That model becomes increasingly risky with advanced surface technologies, particularly when development experts are removed too early. 

Nano-scale surface engineering and biologically active interfaces require ongoing collaboration between science, engineering, quality, and manufacturing teams. These are rarely “set it and forget it” systems. Maintaining quality often requires a level of cross-functional oversight that traditional manufacturing processes do not. In many cases, it also requires evaluating manufacturing assumptions through a different lens. What may appear insignificant at the macro level can have meaningful implications when viewed through a nano-scale perspective. 

This is where a cross-functional team with expertise across both development and manufacturing becomes critical to overall success. In my experience, the organizations that scale most successfully are the ones that integrate manufacturing expertise early and maintain collaboration throughout commercialization. 

Why Consistency Wins

In orthopedic innovation, breakthrough technologies understandably attract attention. But from an operational perspective, developing a technology that can consistently deliver results over time may ultimately be the more difficult feat. 

• Can the technology maintain perf-ormance after years of shelf life?
• Can it withstand inherent production variability?
• Can it integrate into existing supply chains without excessive disruption?
• Can quality systems sustain the process over time? 

These are not secondary questions to simply consider. They are often the deciding factors between technologies that remain niche innovations and those that achieve widespread adoption and support sustainable growth over time. 

Surgeons ultimately depend on consistent product performance for their patients. A technology that performs exceptionally in controlled development environments but inconsistently in commercial production creates operational and clinical risk that cannot be ignored. Operational scalability should not be viewed as a late-stage commercialization exercise. It should be viewed as a core part of technology development.

Closing the Gap Between Innovation and Execution

As surface technologies continue evolving, I believe the industry needs to bring manufacturing and operational considerations into development conversations much earlier, not to slow innovation down, but to make it more sustainable. Questions around cleaning validation, packaging compatibility, sterilization impact, supply chain robustness, and manufacturing scalability should not wait until commercialization planning. They should be part of early feasibility discussions.

This philosophy should be foundational in how a company approaches surface technology development and commercialization. While supporting both new product introductions and existing product conversions across a range of implant designs and manufacturing methods, leading suppliers will understand successful surface integration is rarely about the surface itself. More often, it requires alignment across the broader manufacturing ecosystem. It requires alignment across design, manufacturing, cleaning, packaging, sterilization, quality systems, and operational execution.

In addition, every manufacturer’s situation is different. Some are launching entirely new product lines, while others are evaluating how to incorporate surface technology into mature systems without disrupting established operations or supply chains. In both cases, operational partnership matters. Engaging customers early, evaluating manufacturability risks, identifying process gaps, and developing scalable solutions can significantly reduce friction during commercialization.

Ultimately, the future of orthopedic surface technology will be defined by more than biological performance alone. The technologies that achieve lasting impact will be the ones that successfully close the gap between innovation and manufacturing reality.

More from Nanovis—Rethinking Healing: A Holistic Approach to Orthopedic Surface Design

Joe Roth has been with Nanovis since 2020 and previously served as the company’s quality manager. With 20 years of experience in manufacturing, quality, and operations, he has extensive expertise in process development, manufacturing scale-up, and operational excellence within regulated industries.